TREND: TRial on the Endocrine Activity of Neoadjuvant Degarelix

Sponsor
ETOP IBCSG Partners Foundation (Other)
Overall Status
Completed
CT.gov ID
NCT02005887
Collaborator
(none)
51
7
2
42.7
7.3
0.2

Study Details

Study Description

Brief Summary

The purpose of the this study is to investigate the anti-tumor activity and tolerability of the study medications Degarelix and Triptorelin in premenopausal women receiving preoperative treatment with Letrozole.

Condition or Disease Intervention/Treatment Phase
Phase 2

Detailed Description

RATIONALE Preoperative chemotherapy enables breast-conserving surgery for some patients with breast cancer, and it might be advantageous in several other ways. For example, the response to primary treatment may be used as a prognostic marker, since it has been demonstrated to be associated with a longer disease-free survival (DFS) compared with no response. In particular the degree of response (pathological complete remission (pCR)) predicts overall outcome in terms of DFS.

However, pCR can be achieved only in a minority of patients with estrogen receptor (ER)-positive disease. Studies in the medical literature indicate that pCR rates range from 2% to 10% in those patients whose tumors express ER suggesting that objective response and decrease of Ki67 must be considered within this subset of tumors.

The results of phase II studies and randomized phase III trials have clearly shown that preoperative endocrine therapy is a feasible and safe option among patients with hormone-receptor positive tumors. Letrozole has been shown to induce greater rates of clinical responses and of breast-conserving surgery in postmenopausal women as compared with tamoxifen.

In premenopausal women with ER and progesterone receptor (PgR) positive breast cancer, the preoperative endocrine therapy includes a combination of a gonadotropin-releasing hormone analogue (GnRH) plus tamoxifen. Recent studies suggest that neoadjuvant endocrine therapy with a combination of GnRH analogue and aromatase inhibitors (AIs: letrozole or anastrozole) is effective in selected premenopausal patients. The GnRH analogue, also known as a luteinizing hormone-releasing hormone agonist (LHRH agonist) or LHRH analogue, is a synthetic peptide drug modeled after the human hypothalamic gonadotropin-releasing hormone (GnRH). A GnRH analogue is designed to interact with the GnRH receptor and modify the release of pituitary gonadotropins, follicle-stimulating hormone (FSH) and luteinizing hormone (LH) for therapeutic purposes. Upon administration of a GnRH analogue, an initial stimulating action of the hypophysis occurs - termed a "flare" effect - which eventually causes a paradoxical and sustained drop in gonadotropin secretion. This second effect has been termed "downregulation" and can be observed after about 10 days. While this phase is reversible following cessation of medication, it can be maintained when GnRH agonists' use is continued for a long time. For a select group of patients, there is a delay of approximately 2-4 months before downregulation of the gonadotropins is observed.

Degarelix (INN) or degarelix acetate (USAN) (tradename: Firmagon) is a hormonal therapy approved for the treatment of prostate cancer. Since testosterone, a male hormone, promotes the growth of many prostate tumors, reduction of circulating testosterone to very low (castration) levels is often the treatment goal in the management of advanced prostate cancer. Degarelix, an antagonist of GnRH, has immediate onset of action through binding to GnRH receptors in the pituitary gland and blocking their interaction with GnRH. The result is a fast and profound reduction in LH, FSH and in turn, testosterone suppression. Its activity in suppressing the ovaries of premenopausal women might therefore be faster than other GnRH analogues, possibly by several weeks. The probable difference in onset of action could have significant clinical value for patients who are candidates for short-term neoadjuvant endocrine treatment.

TRANSLATIONAL RESEARCH A tumor block from the diagnostic core biopsy and one from final surgery will be collected and banked for central review and future translational research at the IBCSG Tissue Bank hosted by the European Institute of Oncology in Milan, Italy.

PATIENT-REPORTED SYMPTOMS The patient-reported symptoms (PRS) will be assessed using the Functional Assessment of Cancer Therapy Endocrine Subscale (FACT-ES) comprising 18 items (each has score range from 0 to 4) with a possible maximum total score of 72. Functional Assessment of Chronic Illness Therapy (FACIT) guidelines will be used for scoring and interpretation of the FACT-ES total score. Patients will be asked to complete a PRS Form at baseline (prior to randomization), at day 1 of cycle 2, at day 1 of cycle 4, and prior to surgery.

The objectives are

  • To assess the differences in PRS score over time between the two treatment arms

  • To correlate the estradiol (E2) levels and total PRS score measured on day 1 of cycle 2 and day 1 of cycle 4 of triptorelin or degarelix administration

  • To summarize each of the 18 individual (endocrine symptom) items of the FACT-ES descriptively over time as the proportion of patients with "clinically significant" symptoms (those scoring 3 or 4)

STRATIFICATION Stratification will be performed according to:
  • Age(in years): less than or equal to 39 versus 40 or more

STATISTICAL CONSIDERATIONS To achieve the primary objective, E2 levels will be determined centrally from samples taken at day 1 of the first treatment cycle before the administration of the first dose of degarelix or triptorelin (baseline), and thereafter at 24 and 72 hours, 7 days and 14 days after the first injection, and on day 1 of cycles 2 to 6 before the administration of degarelix or triptorelin.

For sample size calculation, we assume that the cumulative percentages of patients in the triptorelin arm achieving optimal ovarian function suppression (defined as E2 ≤2.72 pg/mL or ≤10 pmol/L) will be 30% within 2 weeks, 60% within 4 weeks and 75% within 8 weeks, and that degarelix will provide more rapid suppression (i.e., 60% within 2 weeks, 95% within 4 weeks and 100% within 8 weeks). Enrollment of 25 patients in each treatment arm will provide at least 90% power to detect a difference in time to optimal ovarian function suppression between the two groups, using a two sample log-rank test with a two-sided significance level of 0.05.

Randomized patients who receive at least one injection of triptorelin or degarelix will be included in the primary analysis. The primary endpoint will be compared between the two treatment arms using a stratified two-sample log-rank test, with age as stratification factor. The distribution of the primary endpoint will be summarized using the method of Kaplan-Meier and the two-sided 95% confidence interval (CI) for the difference in proportion of patients who achieve optimal ovarian function suppression between the two treatment arms at the end of the 1st, 2nd and 4th cycle will also be provided.

The toxicity, changes in Ki67 expression levels, the Preoperative Endocrine Prognostic Index (PEPI) score at the time of surgery, disease response, node-negative disease status at surgery and breast-conserving surgery (BCS) rate will also be summarized and differences assessed between treatment arms with confidence intervals.

The primary endpoint for patient-reported symptoms (PRS) analysis is the total PRS score measured at baseline, day 1 of cycle 2 and day 1 of cycle 4 of triptorelin or degarelix administration, and prior to surgery. The differences in PRS measurements between the two treatment arms over time will be explored using the repeated measures analysis based on generalized estimating equation (GEE) model.

Study Design

Study Type:
Interventional
Actual Enrollment :
51 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Randomized Phase II Trial Evaluating the Endocrine Activity and Efficacy of Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Receiving Letrozole for Primary Endocrine Responsive Breast Cancer
Actual Study Start Date :
Feb 1, 2014
Actual Primary Completion Date :
Aug 25, 2017
Actual Study Completion Date :
Aug 25, 2017

Arms and Interventions

Arm Intervention/Treatment
Experimental: triptorelin + letrozole

Arm A: Triptorelin 3.75 mg i.m. on day 1 every 28 days for 6 cycles + letrozole 2.5 mg/day orally for 6 cycles

Drug: triptorelin
Triptorelin 3.75 mg injected into the muscle on day 1 every 28 days for 6 cycles (1 cycle= 28 days)
Other Names:
  • decapeptyl
  • Drug: letrozole
    Letrozole 2.5 mg orally every day for 6 cycles
    Other Names:
  • femara
  • Experimental: degarelix + letrozole

    Arm B: Degarelix 240 mg s.c. on day 1 of cycle 1, followed by 80 mg s.c. on day 1 of cycles 2 to 6 + letrozole 2.5 mg every day orally for 6 cycles

    Drug: degarelix
    Degarelix 240 mg injected under the skin given as two injections of 120 mg on the first day of treatment, followed by injection of 80 mg on day 1 of cycles 2 to 6 (1 cycle=28 days)
    Other Names:
  • firmagon
  • Drug: letrozole
    Letrozole 2.5 mg orally every day for 6 cycles
    Other Names:
  • femara
  • Outcome Measures

    Primary Outcome Measures

    1. Time to Optimal Ovarian Function Suppression [up to 24 weeks]

      Time from the first injection of degarelix or triptorelin to the first assessment of centrally assessed 17-β-estradiol (E2) level in the range of optimal ovarian function suppression (≤2.72 pg/mL or ≤10 pmol/L) during the 6 cycles of neoadjuvant treatments.

    Secondary Outcome Measures

    1. Ki67 Proliferation Marker Changes [Before day1 of cycle 1 and surgery]

      The percent change in Ki67 expression from pre-treatment diagnostic (baseline) biopsy to surgery, calculated as (surgery-baseline)/baseline*100.

    2. Preoperative Endocrine Prognostic Index (PEPI) Score [After 24 weeks or the time of surgery]

      Preoperative Endocrine Prognostic Index (PEPI) is the sum of the risk points (tumor size, nodal status, Ki67 level, ER status) with a 0-12 score representing the best prognostic feature (0 being the best score; 12 being the worst score), as previously determined to be associated with recurrence-free survival.

    3. Best Overall (Disease) Response [From day 1 of cycle 1 across all time points until disease progression]

      Based on WHO tumor measurement and response criteria [1], measured from the start of treatment across all time points until disease progression or the end of 6 cycles of neoadjuvant therapies, whichever comes first. Response was determined by the IBCSG Head of Medical Affairs. An internal review (IR) form was created to record the final determination on best overall response. Confirmation of partial or complete response by an additional scan was not required in this trial. Best overall response was assessed based on changes in tumor size from baseline to the assessments after 3 and after 6 cycles (denoted as day 1 of cycle 4 and prior to surgery respectively) as measured physically by caliper or ruler and as measured by breast tumor imaging (i.e., bilateral mammography and breast ultrasound).

    4. Percentage of Patients With Node-negative Disease at Surgery [During surgery, an average of 2 hours]

      The number of lymph nodes assessed at surgery minus the number of positives nodes identified, equal to zero.

    5. Percentage of Patients Who Underwent Breast-Conserving Surgery (BCS) [During surgery, an average of 2 hours]

      Whether or not patient undergoes BCS (per Surgery form).

    6. Patient-reported Symptoms (PRS) Outcomes [At baseline, day 1 of cycle 2 and cycle 4 and prior to surgery; cycle 4 reported]

      The patient-reported symptoms (PRS) will be assessed using the Functional Assessment of Cancer Therapy Endocrine Subscale (FACT-ES) comprising 18 items (each has score range from 0 to 4) with a possible minimum total score of 0 and maximum total score of 72 (72 is best). Functional Assessment of Chronic Illness Therapy (FACIT) guidelines will be used for scoring and interpretation of the FACT-ES total score.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Female gender

    • Premenopausal status measured within 14 days Prior to randomization: Estradiol (E2) must be above 54 pg/mL (or above 198 pmol/L

    • Age ≥ 18 years

    • Performance Status - Eastern Cooperative Oncology Group (ECOG) 0-1

    • Histologically confirmed invasive breast cancer: Primary tumor greater than 2 cm Diameter, any nodal stage, no evidence of metastasis (M0)

    • Primary tumor must have ER and PgR >50% of the cells

    • Primary tumor must be HER2-negative (by IHC and/or ISH)

    • Hematopoietic status: Absolute neutrophil count ≥ 1.5 × 109/L, platelet count ≥ 100 × 109/L, hemoglobin ≥ 9 g/dL

    • Hepatic status: Serum total bilirubin ≤ 1.5 × upper limit of normal (ULN), AST and ALT ≤ 2.5 × ULN, Alkaline phosphatase ≤ 2.5 × ULN

    • Renal status: Creatinine ≤ 1.5 ×ULN

    • Negative serum pregnancy test, within 2 weeks (preferably 7 days) prior to randomization.

    • The patient must be willing to use effective non-hormonal contraception after the pregnancy test and up to surgery. Oral, injectable, or implant hormonal contraceptives or medicated IUD are not allowed within 2 months prior to randomization and during the trial.

    • Prior fertility treatment is allowed but must have been stopped at least 12 months before randomization.

    • The patient has completed the baseline patient-reported symptoms questionnaire.

    • Written Informed Consent (IC) must be signed and dated by the patient and the Investigator prior to randomization.

    • The patient has been informed of and agrees to data transfer and handling, in accordance with national data protection guidelines.

    • The patient accepts blood samples to be taken for the determination of the primary endpoint.

    • The patient agrees to make tumor available for submission for central pathology review and for translational studies as part of this protocol

    Exclusion Criteria:
    • Postmenopausal

    • Any hormonal treatment (e.g., oral, injectable, implant, or medicated IUD) in the previous 2 months

    • Presence of HER2 overexpression or amplification

    • Received any prior treatment for primary invasive breast cancer

    • Received any GnRH analog or SERM or AI within 12 months prior to randomization

    • A history of malignant neoplasms within the past 10 years, except for curatively treated,Basal and squamous cell carcinoma of the skin, carcinoma in situ of the cervix, carcinoma in situ of the bladder

    • Previous ipsilateral breast cancer (invasive or in situ) at any time

    • Inflammatory breast cancer

    • Bilateral invasive breast cancer

    • Known history of uncontrolled or symptomatic angina, clinically significant arrhythmias, congestive heart failure, transmural myocardial infarction, uncontrolled hypertension (≥ 180/110), unstable diabetes mellitus, dyspnea at rest, or chronic therapy with oxygen

    • Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject's safety

    • Unresolved or unstable, serious adverse events from prior administration of another investigational drug

    • Active or uncontrolled infection CTCAE v.4 grade 2 or higher

    • Dementia, altered mental status, or any psychiatric condition that would prevent the understanding or rendering of Informed Consent

    • Treatment with an investigational agent must have stopped at least 30 days before randomization.

    • Pregnant or lactating women; lactation has to stop before randomization.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Azienda Ospedaliero-Universitaria Policlinico S. Orsola-Malpighi di Bologna Bologna Italy 40138
    2 Ospedali Galliera Genova Italy 16128
    3 Istituto Europeo di Oncologia, IEO Milano Italy 20141
    4 Salvatore Maugeri Fondation Pavia Italy 27100
    5 Istituto Toscana Tumori Prato Italy 59100
    6 Ospedale degli Infermi Rimini Italy 47037
    7 A.O "Ospedale di Circolo e Fondazione" Macchi Varese Italy 2100

    Sponsors and Collaborators

    • ETOP IBCSG Partners Foundation

    Investigators

    • Study Chair: Silvia Dellapasqua, MD, European Institute of Oncology,Milan,Italy
    • Study Chair: Marco Colleoni, MD, European Institute of Oncology, Milan, Italy

    Study Documents (Full-Text)

    More Information

    Publications

    Responsible Party:
    ETOP IBCSG Partners Foundation
    ClinicalTrials.gov Identifier:
    NCT02005887
    Other Study ID Numbers:
    • IBCSG 41-13
    • 2012-005326-29
    First Posted:
    Dec 9, 2013
    Last Update Posted:
    May 29, 2019
    Last Verified:
    May 1, 2019
    Keywords provided by ETOP IBCSG Partners Foundation
    Additional relevant MeSH terms:

    Study Results

    Participant Flow

    Recruitment Details
    Pre-assignment Detail
    Arm/Group Title Arm A: Triptorelin + Letrozol Arm B: Degarelix + Letrozol
    Arm/Group Description Arm A: Triptorelin 3.75 mg i.m. on day 1 every 28 days for 6 cycles + letrozole 2.5 mg/day orally for 6 cycles Triptorelin: Triptorelin 3.75 mg injected into the muscle on day 1 every 28 days for 6 cycles (1 cycle= 28 days) Letrozole: Letrozole 2.5 mg orally every day for 6 cycles Arm B: Degarelix 240 mg s.c. on day 1 of cycle 1, followed by 80 mg s.c. on day 1 of cycles 2 to 6 + letrozole 2.5 mg every day orally for 6 cycles Degarelix: Degarelix 240 mg injected under the skin given as two injections of 120 mg on the first day of treatment, followed by injection of 80 mg on day 1 of cycles 2 to 6 (1 cycle=28 days) Letrozole: Letrozole 2.5 mg orally every day for 6 cycles
    Period Title: Overall Study
    STARTED 26 25
    COMPLETED 26 23
    NOT COMPLETED 0 2

    Baseline Characteristics

    Arm/Group Title Arm A: Triptorelin + Letrozol Arm B: Degarelix + Letrozol Total
    Arm/Group Description Arm A: Triptorelin 3.75 mg i.m. on day 1 every 28 days for 6 cycles + letrozole 2.5 mg/day orally for 6 cycles Triptorelin: Triptorelin 3.75 mg injected into the muscle on day 1 every 28 days for 6 cycles (1 cycle= 28 days) Letrozole: Letrozole 2.5 mg orally every day for 6 cycles Arm B: Degarelix 240 mg s.c. on day 1 of cycle 1, followed by 80 mg s.c. on day 1 of cycles 2 to 6 + letrozole 2.5 mg every day orally for 6 cycles Degarelix: Degarelix 240 mg injected under the skin given as two injections of 120 mg on the first day of treatment, followed by injection of 80 mg on day 1 of cycles 2 to 6 (1 cycle=28 days) Letrozole: Letrozole 2.5 mg orally every day for 6 cycles Total of all reporting groups
    Overall Participants 26 25 51
    Age (years) [Median (Inter-Quartile Range) ]
    Median (Inter-Quartile Range) [years]
    44.0
    45.0
    44.0
    Sex: Female, Male (Count of Participants)
    Female
    26
    100%
    25
    100%
    51
    100%
    Male
    0
    0%
    0
    0%
    0
    0%
    Race and Ethnicity Not Collected (Count of Participants)
    Count of Participants [Participants]
    0
    0%
    Region of Enrollment (Count of Participants)
    Italy
    26
    100%
    25
    100%
    51
    100%

    Outcome Measures

    1. Primary Outcome
    Title Time to Optimal Ovarian Function Suppression
    Description Time from the first injection of degarelix or triptorelin to the first assessment of centrally assessed 17-β-estradiol (E2) level in the range of optimal ovarian function suppression (≤2.72 pg/mL or ≤10 pmol/L) during the 6 cycles of neoadjuvant treatments.
    Time Frame up to 24 weeks

    Outcome Measure Data

    Analysis Population Description
    [Not Specified]
    Arm/Group Title Arm A: Triptorelin + Letrozol Arm B: Degarelix + Letrozol
    Arm/Group Description Arm A: Triptorelin 3.75 mg i.m. on day 1 every 28 days for 6 cycles + letrozole 2.5 mg/day orally for 6 cycles Triptorelin: Triptorelin 3.75 mg injected into the muscle on day 1 every 28 days for 6 cycles (1 cycle= 28 days) Letrozole: Letrozole 2.5 mg orally every day for 6 cycles Arm B: Degarelix 240 mg s.c. on day 1 of cycle 1, followed by 80 mg s.c. on day 1 of cycles 2 to 6 + letrozole 2.5 mg every day orally for 6 cycles Degarelix: Degarelix 240 mg injected under the skin given as two injections of 120 mg on the first day of treatment, followed by injection of 80 mg on day 1 of cycles 2 to 6 (1 cycle=28 days) Letrozole: Letrozole 2.5 mg orally every day for 6 cycles
    Measure Participants 26 25
    Median (95% Confidence Interval) [days]
    14
    3
    2. Secondary Outcome
    Title Ki67 Proliferation Marker Changes
    Description The percent change in Ki67 expression from pre-treatment diagnostic (baseline) biopsy to surgery, calculated as (surgery-baseline)/baseline*100.
    Time Frame Before day1 of cycle 1 and surgery

    Outcome Measure Data

    Analysis Population Description
    Four patients are not evaluable: two patients did not undergo surgery during trial period, two patients did not have specimen submitted from surgery
    Arm/Group Title Arm A: Triptorelin + Letrozol Arm B: Degarelix + Letrozol
    Arm/Group Description Arm A: Triptorelin 3.75 mg i.m. on day 1 every 28 days for 6 cycles + letrozole 2.5 mg/day orally for 6 cycles Triptorelin: Triptorelin 3.75 mg injected into the muscle on day 1 every 28 days for 6 cycles (1 cycle= 28 days) Letrozole: Letrozole 2.5 mg orally every day for 6 cycles Arm B: Degarelix 240 mg s.c. on day 1 of cycle 1, followed by 80 mg s.c. on day 1 of cycles 2 to 6 + letrozole 2.5 mg every day orally for 6 cycles Degarelix: Degarelix 240 mg injected under the skin given as two injections of 120 mg on the first day of treatment, followed by injection of 80 mg on day 1 of cycles 2 to 6 (1 cycle=28 days) Letrozole: Letrozole 2.5 mg orally every day for 6 cycles
    Measure Participants 25 22
    Median (Inter-Quartile Range) [percentage change]
    -10.0
    -8.0
    3. Secondary Outcome
    Title Preoperative Endocrine Prognostic Index (PEPI) Score
    Description Preoperative Endocrine Prognostic Index (PEPI) is the sum of the risk points (tumor size, nodal status, Ki67 level, ER status) with a 0-12 score representing the best prognostic feature (0 being the best score; 12 being the worst score), as previously determined to be associated with recurrence-free survival.
    Time Frame After 24 weeks or the time of surgery

    Outcome Measure Data

    Analysis Population Description
    Two patients who did not have surgery were not evaluated
    Arm/Group Title Arm A: Triptorelin + Letrozol Arm B: Degarelix + Letrozol
    Arm/Group Description Arm A: Triptorelin 3.75 mg i.m. on day 1 every 28 days for 6 cycles + letrozole 2.5 mg/day orally for 6 cycles Triptorelin: Triptorelin 3.75 mg injected into the muscle on day 1 every 28 days for 6 cycles (1 cycle= 28 days) Letrozole: Letrozole 2.5 mg orally every day for 6 cycles Arm B: Degarelix 240 mg s.c. on day 1 of cycle 1, followed by 80 mg s.c. on day 1 of cycles 2 to 6 + letrozole 2.5 mg every day orally for 6 cycles Degarelix: Degarelix 240 mg injected under the skin given as two injections of 120 mg on the first day of treatment, followed by injection of 80 mg on day 1 of cycles 2 to 6 (1 cycle=28 days) Letrozole: Letrozole 2.5 mg orally every day for 6 cycles
    Measure Participants 26 23
    Median (Inter-Quartile Range) [scores on a scale]
    6.5
    6.0
    4. Secondary Outcome
    Title Best Overall (Disease) Response
    Description Based on WHO tumor measurement and response criteria [1], measured from the start of treatment across all time points until disease progression or the end of 6 cycles of neoadjuvant therapies, whichever comes first. Response was determined by the IBCSG Head of Medical Affairs. An internal review (IR) form was created to record the final determination on best overall response. Confirmation of partial or complete response by an additional scan was not required in this trial. Best overall response was assessed based on changes in tumor size from baseline to the assessments after 3 and after 6 cycles (denoted as day 1 of cycle 4 and prior to surgery respectively) as measured physically by caliper or ruler and as measured by breast tumor imaging (i.e., bilateral mammography and breast ultrasound).
    Time Frame From day 1 of cycle 1 across all time points until disease progression

    Outcome Measure Data

    Analysis Population Description
    [Not Specified]
    Arm/Group Title Arm A: Triptorelin + Letrozol Arm B: Degarelix + Letrozol
    Arm/Group Description Arm A: Triptorelin 3.75 mg i.m. on day 1 every 28 days for 6 cycles + letrozole 2.5 mg/day orally for 6 cycles Triptorelin: Triptorelin 3.75 mg injected into the muscle on day 1 every 28 days for 6 cycles (1 cycle= 28 days) Letrozole: Letrozole 2.5 mg orally every day for 6 cycles Arm B: Degarelix 240 mg s.c. on day 1 of cycle 1, followed by 80 mg s.c. on day 1 of cycles 2 to 6 + letrozole 2.5 mg every day orally for 6 cycles Degarelix: Degarelix 240 mg injected under the skin given as two injections of 120 mg on the first day of treatment, followed by injection of 80 mg on day 1 of cycles 2 to 6 (1 cycle=28 days) Letrozole: Letrozole 2.5 mg orally every day for 6 cycles
    Measure Participants 26 25
    Number (90% Confidence Interval) [percentage of patients]
    46.2
    44.0
    5. Secondary Outcome
    Title Percentage of Patients With Node-negative Disease at Surgery
    Description The number of lymph nodes assessed at surgery minus the number of positives nodes identified, equal to zero.
    Time Frame During surgery, an average of 2 hours

    Outcome Measure Data

    Analysis Population Description
    Two patients who did not have surgery were not evaluated
    Arm/Group Title Arm A: Triptorelin + Letrozol Arm B: Degarelix + Letrozol
    Arm/Group Description Arm A: Triptorelin 3.75 mg i.m. on day 1 every 28 days for 6 cycles + letrozole 2.5 mg/day orally for 6 cycles Triptorelin: Triptorelin 3.75 mg injected into the muscle on day 1 every 28 days for 6 cycles (1 cycle= 28 days) Letrozole: Letrozole 2.5 mg orally every day for 6 cycles Arm B: Degarelix 240 mg s.c. on day 1 of cycle 1, followed by 80 mg s.c. on day 1 of cycles 2 to 6 + letrozole 2.5 mg every day orally for 6 cycles Degarelix: Degarelix 240 mg injected under the skin given as two injections of 120 mg on the first day of treatment, followed by injection of 80 mg on day 1 of cycles 2 to 6 (1 cycle=28 days) Letrozole: Letrozole 2.5 mg orally every day for 6 cycles
    Measure Participants 26 23
    Number (90% Confidence Interval) [percentage of patients]
    34.6
    43.5
    6. Secondary Outcome
    Title Percentage of Patients Who Underwent Breast-Conserving Surgery (BCS)
    Description Whether or not patient undergoes BCS (per Surgery form).
    Time Frame During surgery, an average of 2 hours

    Outcome Measure Data

    Analysis Population Description
    Two patients who did not have surgery were not evaluated
    Arm/Group Title Arm A: Triptorelin + Letrozol Arm B: Degarelix + Letrozol
    Arm/Group Description Arm A: Triptorelin 3.75 mg i.m. on day 1 every 28 days for 6 cycles + letrozole 2.5 mg/day orally for 6 cycles Triptorelin: Triptorelin 3.75 mg injected into the muscle on day 1 every 28 days for 6 cycles (1 cycle= 28 days) Letrozole: Letrozole 2.5 mg orally every day for 6 cycles Arm B: Degarelix 240 mg s.c. on day 1 of cycle 1, followed by 80 mg s.c. on day 1 of cycles 2 to 6 + letrozole 2.5 mg every day orally for 6 cycles Degarelix: Degarelix 240 mg injected under the skin given as two injections of 120 mg on the first day of treatment, followed by injection of 80 mg on day 1 of cycles 2 to 6 (1 cycle=28 days) Letrozole: Letrozole 2.5 mg orally every day for 6 cycles
    Measure Participants 26 23
    Number (90% Confidence Interval) [percentage of patients]
    42.3
    52.2
    7. Secondary Outcome
    Title Patient-reported Symptoms (PRS) Outcomes
    Description The patient-reported symptoms (PRS) will be assessed using the Functional Assessment of Cancer Therapy Endocrine Subscale (FACT-ES) comprising 18 items (each has score range from 0 to 4) with a possible minimum total score of 0 and maximum total score of 72 (72 is best). Functional Assessment of Chronic Illness Therapy (FACIT) guidelines will be used for scoring and interpretation of the FACT-ES total score.
    Time Frame At baseline, day 1 of cycle 2 and cycle 4 and prior to surgery; cycle 4 reported

    Outcome Measure Data

    Analysis Population Description
    All patients who received at least one dose of trial treatment and had at least one FACT-ES assessment were included in the analysis
    Arm/Group Title Arm A: Triptorelin + Letrozol Arm B: Degarelix + Letrozol
    Arm/Group Description Arm A: Triptorelin 3.75 mg i.m. on day 1 every 28 days for 6 cycles + letrozole 2.5 mg/day orally for 6 cycles Triptorelin: Triptorelin 3.75 mg injected into the muscle on day 1 every 28 days for 6 cycles (1 cycle= 28 days) Letrozole: Letrozole 2.5 mg orally every day for 6 cycles Arm B: Degarelix 240 mg s.c. on day 1 of cycle 1, followed by 80 mg s.c. on day 1 of cycles 2 to 6 + letrozole 2.5 mg every day orally for 6 cycles Degarelix: Degarelix 240 mg injected under the skin given as two injections of 120 mg on the first day of treatment, followed by injection of 80 mg on day 1 of cycles 2 to 6 (1 cycle=28 days) Letrozole: Letrozole 2.5 mg orally every day for 6 cycles
    Measure Participants 26 25
    Number (90% Confidence Interval) [units on a scale]
    64
    62

    Adverse Events

    Time Frame Adverse events (AE) forms were submitted at the end of every cycle (28 days) and 30 days after surgery. All patients submitted AE data during 6 cycles of treatment period when available.
    Adverse Event Reporting Description Adverse events were collected using CTCAE v4.0. Each targeted AE will be classified according to the maximum grade of the event while on trial treatment (grade 0,1,2,3,4,5; where 0=no report). Other grade 3-5 AEs will be classified according to the maximum grade of any reported other AE.
    Arm/Group Title Arm A: Triptorelin + Letrozol Arm B: Degarelix + Letrozol
    Arm/Group Description Arm A: Triptorelin 3.75 mg i.m. on day 1 every 28 days for 6 cycles + letrozole 2.5 mg/day orally for 6 cycles Triptorelin: Triptorelin 3.75 mg injected into the muscle on day 1 every 28 days for 6 cycles (1 cycle= 28 days) Letrozole: Letrozole 2.5 mg orally every day for 6 cycles Arm B: Degarelix 240 mg s.c. on day 1 of cycle 1, followed by 80 mg s.c. on day 1 of cycles 2 to 6 + letrozole 2.5 mg every day orally for 6 cycles Degarelix: Degarelix 240 mg injected under the skin given as two injections of 120 mg on the first day of treatment, followed by injection of 80 mg on day 1 of cycles 2 to 6 (1 cycle=28 days) Letrozole: Letrozole 2.5 mg orally every day for 6 cycles
    All Cause Mortality
    Arm A: Triptorelin + Letrozol Arm B: Degarelix + Letrozol
    Affected / at Risk (%) # Events Affected / at Risk (%) # Events
    Total 0/26 (0%) 0/25 (0%)
    Serious Adverse Events
    Arm A: Triptorelin + Letrozol Arm B: Degarelix + Letrozol
    Affected / at Risk (%) # Events Affected / at Risk (%) # Events
    Total 0/26 (0%) 0/25 (0%)
    Other (Not Including Serious) Adverse Events
    Arm A: Triptorelin + Letrozol Arm B: Degarelix + Letrozol
    Affected / at Risk (%) # Events Affected / at Risk (%) # Events
    Total 23/26 (88.5%) 23/25 (92%)
    Blood and lymphatic system disorders
    Anemia 1/26 (3.8%) 1 0/25 (0%) 0
    Gastrointestinal disorders
    Nausea 1/26 (3.8%) 1 4/25 (16%) 4
    General disorders
    Fatigue 3/26 (11.5%) 3 1/25 (4%) 1
    Injection Site Reaction 0/26 (0%) 0 6/25 (24%) 7
    Investigations
    Alanine Aminotransferase (ALT) 1/26 (3.8%) 1 0/25 (0%) 0
    Musculoskeletal and connective tissue disorders
    Arthralgia 14/26 (53.8%) 16 8/25 (32%) 9
    Myalgia 2/26 (7.7%) 2 1/25 (4%) 1
    Psychiatric disorders
    Anxiety 2/26 (7.7%) 2 2/25 (8%) 2
    Depression 1/26 (3.8%) 1 2/25 (8%) 2
    Insomnia 3/26 (11.5%) 4 6/25 (24%) 6
    Reproductive system and breast disorders
    Vaginal Dryness 1/26 (3.8%) 1 1/25 (4%) 1
    Vascular disorders
    Hot Flashes/Flushes 18/26 (69.2%) 18 20/25 (80%) 23
    Hypertension 1/26 (3.8%) 1 3/25 (12%) 3

    Limitations/Caveats

    [Not Specified]

    More Information

    Certain Agreements

    Principal Investigators are NOT employed by the organization sponsoring the study.

    There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

    Results Point of Contact

    Name/Title Meredith M. Regan
    Organization International Breast Cancer Study Group
    Phone +1 617-632-3012
    Email mregan@jimmy.harvard.edu
    Responsible Party:
    ETOP IBCSG Partners Foundation
    ClinicalTrials.gov Identifier:
    NCT02005887
    Other Study ID Numbers:
    • IBCSG 41-13
    • 2012-005326-29
    First Posted:
    Dec 9, 2013
    Last Update Posted:
    May 29, 2019
    Last Verified:
    May 1, 2019